Skip to main content
main-content

02-10-2017 | Breast cancer | Article

Immunotherapy Approaches to Breast Cancer

Journal:
Current Breast Cancer Reports

Authors: April Swoboda, Rita Nanda

Publisher: Springer US

Abstract

Activating the immune system to eradicate breast cancer has emerged as a promising treatment strategy, and immune checkpoint inhibition has demonstrated activity in both advanced and early stage disease. Here we review recent clinical trial results of immunotherapy approaches to treat breast cancer.
A number of trials of immune checkpoint inhibitors, both as monotherapy and in combination with other therapies, have been reported. While response rates with monotherapy in the advanced stage setting are relatively low, the durability of responses observed is remarkable. While PD-L1 positivity enriches for responders, it is not a consistent predictor of response. Response appears to correlate more strongly with tumor-infiltrating lymphocyte (TIL) density.
Immune checkpoint inhibition alone and in combination with chemotherapy appears well tolerated with manageable side effects. Treatment clearly benefits a subset of patients, and more precise biomarkers of response are needed.

Please log in to get access to this content

Related topics